Regulatory Exclusivity: NEW STRENGTH
✉ Email this page to a colleague
Drugs with New Strength Regulatory Exclusivity
Click here to exclude patents covering these drugs from this list
| Applicant | Tradename | Generic Name | NDA | Approval Date | Type | Patent No. | Patent Expiration | Exclusivity Expiration | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | 020263 | Apr 14, 2023 | RX | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | NEW STRENGTH |
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | 020263 | Apr 14, 2023 | RX | 9,617,303 | ⤷ Start Trial | ⤷ Start Trial | NEW STRENGTH |
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | 020263 | Apr 14, 2023 | RX | 8,921,326 | ⤷ Start Trial | ⤷ Start Trial | NEW STRENGTH |
| >Applicant | >Tradename | >Generic Name | >NDA | >Approval Date | >Type | >Patent No. | >Patent Expiration | >Exclusivity Expiration | >Patented / Exclusive Use |
